NCT02691325 - Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK2269557 Administered Via the ELLIPTA Dry Powder Inhaler to Healthy Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 14, 2016

Primary Completion Date

June 5, 2016

Study Completion Date

June 5, 2016

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

GSK2269557 ELLIPTA DPI

GSK2269557 ELLIPTA DPI contains GSK2269557 blended with lactose and magnesium stearate. This will be supplied in two strength of 100 mcg per blister.

DRUG

Placebo ELLIPTA DPI

Placebo ELLIPTA DPI contains lactose.

DRUG

Activated charcoal

The activated charcoal will be supplied by the clinical site. Charcoal will be administered as a suspension of 5 gram activated charcoal in 40 mL of water. The suspension will be made to drunk, in its entirety.

Trial Locations (1)

21225

GSK Investigational Site, Baltimore